All three cooperation partners possess special expertise in various fields ranging from basic to clinical research. The DZNE can contribute special know-how in the area of biomarkers and clinical studies. Prof. Pierluigi Nicotera, Scientific Director and Chairman of the Executive Board at the DZNE, is thrilled that the institution can contribute to the effort:
“This cooperation is of great importance for German research on neurodegenerative diseases. We hope to be able to contribute our expertise to develop new strategies to preventing and curing these diseases.” Prof. Nicotera emphasised that common technological platforms and the international standardisation of approaches are crucial to facilitating the transfer of fundamental discoveries into patient benefits.
To ensure that the results are applied in clinics as soon as possible, the German Federal Ministry of Education and Research (BMBF) has tasked the DZNE with working closely with university hospitals all over Germany. “The DZNE has intensified research on neurodegenerative diseases in Germany, improved the coordination of efforts and ensured that research is aligned with the requirements of clinical practice,” said Dr Helge Braun, Parliamentary State Secretary at the BMBF. But he pointed out that international partnerships are needed to solve the scientific and clinical issues regarding dementia. “Therefore we wholeheartedly applaud the pooling of resources across borders. The partnership between the MRC, CIHR and DZNE sets new international standards,” State Secretary Braun said at the press conference in Berlin. The British and Canadian governments also support the partnership. The two countries were represented by Christopher MacLean, Commercial Counsellor at the Canadian embassy, and British Ambassador Sir Michael Arthur, who said: “I am delighted that the UK – represented by the Medical Research Council – is participating in this international partnership. In a time of increasingly aging societies, new preventative strategies and innovative therapies for the treatment of neurodegenerative diseases are becoming more and more important.”
The Medical Research Council has injected significant funding to neurodegenerative research since that this area was reorganised in 2008. “We welcome this exciting opportunity to join with aligned activities in Germany and Canada,” said Prof. Chris Kennard, Chair of the MRC Neurosciences and Mental Health Board. “It’s through first-class international partnerships such as this one that we will build on our knowledge base and accelerate our understanding to more rapidly combat these debilitating neurodegenerative diseases.” Prof. Kennard went on to say that the links between the respective centres of excellence will create an international network that will enable them to attract the best scientists, provide access to cutting-edge technologies, standardise methods and their application and promote the highest level of quality in international research. The MRC can contribute a wealth of experience in working with animal models. Even at the basic research stage, standardised models and methods are crucial to ensure that findings can be compared.
The CIHR conducts both basic and clinical research and is working to standardise imaging methods and the evaluation of the images they generate. “We are proud to work with our colleagues in Germany and the UK to fund research addressing neurodegenerative disorders, in particular on Alzheimer’s disease. We firmly believe that it will require a concerted common research effort to better understand these disorders, improve diagnosis and treatment, and ultimately find a cure for diseases that affect millions of people,” said Dr Rémi Quirion, Executive Director of the International Collaborative Research Strategy for Alzheimer's Disease at the Canadian Institutes of Health Research.
To reach their goals, each of the three centres will allocate 1 million pound. This will serve as starting capital to finance various measures in the three centres. In addition to workshops and the compilation of guidelines, the money will also be specifically used to fund projects in the centres that work according to these guidelines and methods and will advance the research field as a whole. Reactions to the initiative launched by the three partner institutions have been favourable in other countries, and negotiations are underway with other European research organisations.
The German Centre for Neurodegenerative Diseases belongs to the Helmholtz Association and is funded by federal and state governments in relation 90:10.Common press release of the
Sonja Jülich-Abbas | idw
Water forms 'spine of hydration' around DNA, group finds
26.05.2017 | Cornell University
How herpesviruses win the footrace against the immune system
26.05.2017 | Helmholtz-Zentrum für Infektionsforschung
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
26.05.2017 | Life Sciences
26.05.2017 | Life Sciences
26.05.2017 | Physics and Astronomy